Followers | 50 |
Posts | 1912 |
Boards Moderated | 0 |
Alias Born | 07/08/2014 |
Wednesday, July 30, 2014 10:05:25 AM
The term of the agreement, signed by James C. Vowler President & CEO of Unique and by Sumair Mitroo, CEO of Larasan, covers the period April 22, 2014 through July 22, 2015, with the option of continuation.
Dr. M. S. Reddy, Senior Advisor of Unique Pizza and Subs Corporation, said, "We have been speaking with Sumair since the beginning of the year about his company's immense distribution network and its ability to distribute our industry leading gourmet quality Unique pizzas. This agreement is a big step towards getting our product to market and we look forward to working with Sumair and his team. I have been working with the pizza industry for more than 40 years and I have contributed to the success and growth of many of the industry leaders. I have now found what I believe the pizza community has always needed a company that understands what quality really means. Jim has a passion and understanding of the pizza business like no one I have ever met and his drive for success without compromise in quality while maintaining integrity and loyalty is the reason I am on board."
Larasan's CEO, Sumair Mitroo, said, "Although Larasan is a pharmaceutical company with its own line of products that combine nature and bio-science to increase health, we will distribute other products that connect with this vision. People around the world love pizza, and the demand is there for a gourmet and healthy pizza that can be served quickly. After meeting the team at Unique Pizza, I was quickly convinced about their capabilities to fill this demand. Jim is very driven and focused on improving his pizza business, and Dr. Reddy is already well known for his contributions in the pizza industry with his specialized cheese formulations. Moreover, Dr. Reddy's deep knowledge and expertise in probiotics will make significant impact on the success of this venture. Our team is excited to work with Unique Pizza and distribute a truly unique pizza in China and Asia."
About Larasan Pharmaceutical Corporation
Larasan is a nature-based pharmaceutical company with a broad range of transdermal (skin patch), oral, and liquid OTC products, for the prevention and/or treatment of pain, performance, bug bites, and energy. Its products combine nature and bio-science through improved delivery systems to increase health. Based in the US with operations in China, Larasan is an early stage pharmaceutical company with distribution in the US and Asia. For more information, visit www.larasan.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward- looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM